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Intensive Care of Liver Transplant Patients 
A. Recent advances in human orthotopic liver transplantation 
1. Introduction and historical perspective 
The first human liver transplantation was performed by Thomas 
Starzl in 1963. 1 During the next 12 years, however, only 169 additional 
liver transplantations were performed. 2 During this early interval, 
difficulties with donor liver procurement, surgical technique, and 
postoperative rejection placed the future of liver transplantation in 
doubt. Nevertheless, as experience grew and new techniques developed in 
liver transplantation, the number of patients successfully undergoing 
this procedure accelerated. Accordingly, the 1983 Consensus Development 
Panel at the NIH concluded that liver transplantation was an acceptable 
therapeutic modality for the treatment of end-stage liver fai1ure. 3 
Associated with this acceptance, the number of centers in the United 
States performing liver transplantations increased several fold: by the 
end of 1985, 1441 liver transplant procedures had been performed (fig. 
1). Similarly, at the University of Pittsburgh the number of liver 
transplant procedures has grown each year (fig. 2). A 1984 survey by 
Starz1 et al. 4 revealed that since the start of human liver 
transplantation in 1963, 269 (47.3%) of 569 North American recipients 
were still alive. The overall l-year survival improved from 32.9% in 
1979 to 75% in 1984. During the years 1981 to 1985, 653 liver 
transplantations were performed at the University Health Center of 
Pittsburgh. During these 5 years, our postoperative care in the 
intensive care unit (ICU) evolved on the basis of numerous observations 
4 
of the variable postoperative course of these patients. lCU care is 
also determined to a large extent by the surgical procedure, which has 
seen significant changes over the last 5 years. The first part of this 
chapter will describe recent trends in liver transplantation as they may 
reflect on ICU care, while the second part will focus on the specifics 
of postoperative management. 
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2. Patient population and pretransplantation care in the leU 
a. End-stage liver failure as a disease 
Patients awaiting liver transplantation are usually chronically 
ill, as would be expected from the indications for liver transplantation 
(fig. 3). When portal hypertension is present, gastrointestinal 
hemorrhage is common. Most adult liver transplant candidates have had 
at least one episode of acute upper gastrointestinal bleeding. 
Similarly, most have abnormal coagulation profiles, hypoalbuminemia, and 
an altered cardiovascular profile that reflects a high output, low 
peripheral vascular resistance state. It has recently been suggested 
that end-stage liver failure predisposes to multiple orgaq system 
failure. 5 ,6 If so, then our liver transplant candidates are at an 
increased risk to develop remote organ system failure while awaiting 
surgery. Recently, Matuschak and Martin7 described the cardiovascular 
response to sepsis of patients with end-stage liver failure. They found 
no difference in the hemodynamic profile between stable preoperative 
patients awaiting liver transplantation and similar patients with liver 
failure during or after an acute septic episode. This finding 
underscores the previously held clinical impression that it is difficult 
to diagnose sepsis in patients with liver failure. More important, 
however, these data suggest that end-stage liver failure coexists with a 
generalized toxemia due to failure of hepatic defense and clearance 
mechanisms. In further support of this hypothesis, Matuschak et al. 8 
found that when patients with end-stage liver failure developed 
hypoxemic respiratory failure, (i.e., adult respiratory distress 
syndrome) their clinical course uniformly led to death. That this 
lethal interaction may be reversed by liver transplantation is suggested 
by Esquivel et al. 9 who found that 9 of 22 children (40%) with liver 
failure and remote organ failure survived liver transplantation. Given 
the high mortality of multiple organ system failure, these results 
suggest that an irreversible process may be reversed by changing the 
internal environment. 
b. Treatment for metabolic diseases 
Perhaps the most exciting application of liver transplantation is 
in the treatment of metabolic diseases (inborn errors of metabolism). 
If a metabolic disease damages the liver, then such patients have clear 
benefit from liver transplantation. Since the mortality after liver 
transplantation is decreasing, it may become reasonable in the future to 
transplant livers in patients who are not yet in end-stage liver 
failure, but have a fatal or a very disabling primary metabolic 
disorder. Patients with alpha-l antitrypsin deficiency and tyroseinemia 
have not only benefited from having their failing liver replaced, but 
have also been cured of their underlying metabolic disease. 4 Patients 
with other metabolic diseases, such as familial hypercholesterolemia, 
also may benefit from liver transplantation. 10 A partial list of these 
diseases is given in table 1. 
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c. HLA tissue typing 
Experience with both renal and cardiac allograft transplantation 
suggests that human 1ymph?cyte antigen (HLA) matching is important for 
subsequent donor organ viabi1ity.ll Nevertheless, an early study at our 
institution failed to demonstrate any relation between HLA compatibility 
or positive cross-match and liver transplant survival. 2 In fact, 
experience with combined liver-kidney transplants at our institution 
suggests that preformed donor-specific antibodies are removed from the 
circulation by the donor liver without apparent adverse effects. 12 In 
contrast, Knechtle et al. 13 found that under certain instances, the 
liver allograft may undergo hyperacute rejection. Recently, Markus et 
al. 14 reexamined the relation between HLA compatibility and liver 
transplant survival in our institution between March 1980 and December 
1985 (667 liver transplantations in 517 patients). Complete data were 
available for HLA-A and B antigens in 332 donor-recipient pairs. 
Survival of primary grafts with no HLA-A antigen mismatch was less than 
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survival of those with one or two HLA-A antigen mismatches (fig. 4). 
The HLA-B data showed no effect of compatibility on liver survival. 
Complete typing data were available also for HLA-DR antigens in 292 
donor-recipient combinations. Again, one and two DR-mismatched liver 
a1lographs had a better I-year survival than HLA-DR-matched patients 
(fig. 5). These findings suggest that histocompatibility does not 
improve graft survival and may adversely affect liver transplants. 
Similarly, successful liver transplantation across ABO blood groups from 
cross-match positive donors suggests a relative resistance of the liver 
allograft to the deleterious effects of ABO and donor-specific 
antibodies. lS ,16 
d. Viral hepatitis 
Liver transplantation in patients with cirrhosis due to viral 
hepatitis is controversial. Despite the fact that the liver, which 
houses the major viral "load", is removed during liver transplantation 
and that the circulation is flushed with large quantities of blood and 
plasma products, in our experience many of these patients have a 
persistent hepatitis B surface antigenemia postoperatively and develop 
evidence of recurrent chronic hepatitis in the newly transplanted 
liver. 17 Until it is shown that the virus can be eliminated in e 
antigen-positive patients, transplantation remains controversial for 
this group. At present, use of antiviral therapy associated with liver 
transplantation in this group of patients is being examined. 
e. Age limitations 
Although 55 years had been the arbitrary cut-off point for liver 
transplantation, significantly older individuals recently have been 
considered as candidates. The survival of patients following liver 
transplantation does not correlate with age (fig. 6). In our 
institution, the oldest patient to receive a liver transplant was 76 
years old and she remains well after 6 months. These older patients may 
have concomitant cardiac, pulmonary, and renal diseases, however, that 
may complicate perioperative therapy. 
3. Surgical procedure - Improvements in technique 
a. Donor liver management 
Once a patient's condition is considered hopeless and brain death 
is imminent, the focus of care is directed at donor organ maintenance. 
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After brain death certification, all measures are directed at preserving 
donor organs, not neurologic function. In the operating room during 
organ procurement, the donor's cardiac output and oxygenation should be 
maximized. Extensive surgical dissection in the chest and abdomen are 
performed before cold flushing with the preservation solution. This 
sequence is used to minimize ischemic injury.lS Although numerous 
groups have attempted to prolong the ischemic time limit by altering the 
preservation solution, none has been shown to be superior to Euro-
Collins solution. 19 The primary goal in organ procurement is to 
minimize organ ischemic time during and after organ harvesting. 
b. Veno-venous bypass without systemic anticoagulation. 
The anhepatic phase of liver transplantation is the time from 
removal of the native liver to return of blood flow to the donor liver. 
During this time, the inferior vena cava is cross-clamped both at the 
diaphragm and above the renal veins. The portal vein is also clamped. 
This procedure results in an almost complete cessation of venous return 
from below the diaphragm, excepting the flow that reaches the right 
atrium via the azygos veins and other co11atera1s. These occlusions of 
the portal vein and inferior vena cava result in: 1) a significant 
decrease in cardiac output due to pooling of blood below the diaphragm, 
2) marked deterioration in renal function because of renal venous 
occlusion, and 3) worsening of portal venous hypertension, which may 
result in greater blood loss during the entire procedure. 
Because of these considerations, we began using, in adult liver 
transplantations, a heparin-bonded veno-venous bypass system that 
drained both the inferior vena cava and portal vein through a 
centrifugal force pump into an axillary vein. 20 Fifty-seven patients 
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supported with veno-venous bypass were compared with a control group of 
63 previous patients who had liver transplantation without bypass. 
Although long-term (90-day) survival was similar in both groups, the 
non-bypass group required more blood products (33 ± 25 vs. 19 ± 8 units, 
x ± SD, p < 0.01) and had a higher serum creatinine on the third 
postoperative day (3.0 vs. 1.5 mg/dl). Although such factors as 
surgical experience and patient selection also may have affected these 
results, this study suggests that veno-venous bypass improves 
postoperative status after liver transplantation. Not all centers use 
veno-venous bypass. Wall et al. 2l reported their results in 61 liver 
transplantations without veno-venous bypass. They found no.incidence of 
renal failure after liver transplantation in those patients with good 
renal function before surgery. Patients with preoperative hepatorenal 
syndrome required dialysis postoperatively. In agreement with Griffith 
et a1. ,20 Wall et al. 2l found that both mean arterial pressure and 
cardiac output decreased during the anhepatic phase when veno-venous 
bypass was not used. From these studies, it is unclear whether veno-
venous bypass improves postoperative results. However, our experience 
with a large series of high risk patients suggests that improved 
operative survival of many of these patients may be related to routine 
use of veno-venous bypass. Furthermore, veno-venous bypass allows 
surgeons-in-training to perform the difficult vascular anastomoses 
without undue time constraints. 
c. Biliary tract reconstruction 
Problems associated with the biliary tract anastomosis are the 
most common and may be difficult to correct. Today all biliary tract 
reconstructions are performed by either a choledocho-cho1edochostomy 
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with aT-tube stent or a choledochojejunostomy to a Roux-en-Y limb of 
jejunum (fig. 7). Bile duct complications have decreased in frequency 
with this standardized reconstruction. 22 The biliary tree is also 
flushed during procurement of the liver to decrease the subsequent 
development of biliary sludge. Casts may still form within the biliary 
tract up to 8 weeks after transplantation. Intraoperative attention to 
preserving the blood supply to the donor common bile duct improves the 
integrity of the biliary anastomosis. Finally, an intraoperative 
cholangiogram is performed in most patients and aids in identifying 
technical problems for immediate correction in the OR. 
d. Rapid infusion system 
Liver transplantation often requires the transfusion of massive 
quantities of blood over very short intervals to maintain adequate 
cardiac output. Transfusion requirements vary by patient, previous 
surgery, and skill of the surgeon. In the period 1983 through 1985 our 
experience with 200 adult liver transplant recipients showed that 75% 
required more than 10 units of blood intraoperatively, 30% required more 
than 30 units, and 6% more than 100 units. 23 Standard transfusion 
methods are not able to infuse warm blood rapidly enough for this 
procedure. Accordingly, Sassano in collaboration with HaemoneticsR 
Corporation developed a device that could deliver diluted warm blood at 
rates up to 2000 ml/min. This device is called the Rapid Infusion 
System. 
The system infuses a mixture of 2 units packed red blood cells 
(600 ml), 2 units fresh frozen plasma (400 ml), and 500 ml PlasmalyteR 
(total volume, 1500 ml). This solution was selected to provide adequate 
oxygenation and minimize viscosity. The final hematocrit 1s 
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approximately 28%. We use the Rapid Infusion System in most adults 
undergoing liver transplantation but not in children since their 
transfusion requirements are less. Its ability to easily infuse warm 
blood at the required rate has made it invaluable in the intraoperative 
management of these patients. Its use in other situations where massive 
blood transfusions are required is being investigated. When the the 
Rapid Infusion System is used, most patients have a hematocrit in the 
immediate postoperative state equal to that of the blood mixture (28%). 
Although the primary advantage of the Rapid Infusion System is the 
adequate infusion of warm blood with minimal number of personnel, it 
also tends to maintain more stable intraoperative hemodynamics, which 
may be reflected postoperatively in better overall organ function. 
e. Postperfusion syndrome 
Reperfusion of the graft liver after the anhepatic phase is 
frequently associated with cardiovascular collapse. These dramatic 
cardiovascular changes, termed the postperfusion syndrome, are 
characterized by systemic hypotension, bradycardia, increases in central 
venous pressure (CVP) and pulmonary capillary wedge pressure (PCWP) , and 
a decrease in calculated systemic vascular resistance. These changes 
may occur within 30 seconds of reperfusion and last from 5 to 30 
minutes. 24 The cause of the postperfusion syndrome is unknown but has 
been postulated to be the washout of cold, high potassium-containing, 
acidic fluid from the donor liver. 25 ,26 To define the determinants of 
the postperfusion syndrome, Aggarwal et al. 24 studied 69 consecutive 
liver transplantations. They defined the postperfusion syndrome as a 
sudden decrease in mean arterial pressure (MAP) greater than or equal to 
30% for at least 1 minute within the first 5 minutes after umclamping. 
12 
The postperfusion syndrome occurred in 20 patients (30t) (responders). 
This subgroup also had a higher potassium level (5.3 ± 0.8 vs. 4.0 ± 0.5 
mEq/L, p < 0.5) than the nonresponder group. All patients demonstrated 
increases in potassium and decreases in both pH and blood temperature 
after reperfusion. Although the changes in potassium level were 
different between the two subgroups, they did not explain most of the 
variance in MAP. Thus, factors other than hyperkalemia may be involved 
in the postperfusion syndrome. That the postperfusion occurred in only 
20% of the patient sample,24 as opposed to 50% in previous studies,25,26 
suggests that attention to all intraoperative details, including ionized 
calcium, blood volume and acid-base balance, may minimize this serious 
complication. 
4. Postoperative care: Immunosuppression with cyclosporine and OKT-3 
One of the major breakthroughs in the postoperative management of 
organ transplantation was the introduction of cyclosporine. Previously, 
the immunosuppressant regimen was a combination of steroids, 
azathioprine, and pulse therapy with rabbit antithymus globulin (RATG). 
With the substitution of cyclosporine for azothioprine, overall survival 
of primary liver transplants improved from 16.5% to 68.6% (table 2). 
Actuarial survival was also superior with cyclosporine (fig. 8). At 
present, all patients receive cyclosporine as the mainstay of 
immunosuppression. 
In an attempt to further improve liver survival, Starz1 and Fung27 
instituted a randomized trial of mouse anti-human T-cell antibody (OKT-
3) for treatment of acute allograft rejection. By June 1986, 250 liver 
transplant patients had received a course of OKT_3. 28 Baseline 
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immunosuppression consisted of cyclosporine and steroids. Patients were 
separated by time of rejection episode into group 1, less than 10 days 
postoperatively; group 2, between 10 days and 3 months postoperatively; 
and group 3, greater than 3 months after surgery. Results are shown in 
table 3. The maximal beneficial response occurred in group 2 patients, 
in whom cell-mediated rejection was the primary cause of postoperative 
liver allograft dysfunction. Rejection is a major factor influencing 
the need for retransplantation. 29 The rate of retransplantation was 
greatly diminished in group 2 patients. This group represented the 
period during which cell-mediated rejection commonly occurs. The high 
rate of retransplantation in groups 1 and 3 probably reflects the 
inability of OKT-3 to reverse other causes of liver failure, since the 
survival rate of transplanted livers in groups 1 and 3 was similar to 
that of a historical control group that received no OKT-3. Thus OKT-3, 
in conjunction with cyclosporine and steroid, has improved the treatment 
of hepatic allograph rejection due to cell-mediated immune mechanisms. 
In patients with impending renal failure because of cyclosporine renal 
toxicity, OKT-3 also has been used to maintain immunosuppression, 
allowing cyclosporine dosage to be reduced. 
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B. Postoperative intensive care of the liver transplant patient 
The postoperative care of the liver transplant patient in the lCU 
is similar in many ways to the routine postoperative care of any patient 
who has undergone extensive intraabdominal surgery. Strict attention is 
given to intravascular fluid status, electrolyte balance, coagulation, 
liver and renal function, and cardiovascular performance. We closely 
monitor MAP, PGWP, CVP, arterial blood gases, cardiac rhythm, cardiac 
output, and urine output, as well as the output from all surgical 
drains. Therapy is directed initially at achieving hemodynamic 
stability by the titration of routine resuscitative care, which is 
guided by clinical signs, laboratory data, and the invasive hemodynamic 
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monitoring mentioned above. Beyond this resemblance to the routine 
postoperative patient care in the rcu, the liver transplant patient has 
unique problems that stem from the newly transplanted liver and the 
necessity of immunosuppression. 
The routine orders for care of the postoperative liver transplant 
patient are based on standard principles of surgical management (table 
4). Electrocardiogram (EGG), and arterial, central venous, and 
pulmonary arterial pressures are monitored continuously, as are 
respiratory variables during mechanical ventilation. Vital signs and 
fluid balance are recorded frequently, because these patients are often 
unstable in the immediate postoperative period. Many patients have 
oliguria in the first 24- to 48-hour period because of intraoperative 
blood loss and its replacement as well as transient hypotension and/or 
inferior vena caval cross-clamping. Patients may need furosemide and/or 
colloid therapy during this interval. Excessive use of crystalloids, 
lS 
however, can result in pulmonary edema. Therefore, fluids are 
administered as necessary to maintain CVP at approximately 10 cm H20. 
Hypertension is a common postoperative problem. We use 
hydralazine and beta-adrenergic blocking agents such as labetalol and 
propranolol as initial antihypertensive therapy. These agents are given 
as intravenous boluses and titrated to effect. In patients who require 
other antihypertensive therapy because they either cannot receive the 
above agents or are refractory to them, we use minoxidil, c1onidine, and 
captopril. We avoid using alpha methyldopa because of its hepatotoxic 
potential. In acute hypertensive emergencies, nifedipine, 10 mg 
sublingually, is a useful immediate agent in addition to more definitive 
long-term therapy is given. In cases of refractory hypertension, 
labetolol can be given intravenously as 20 mg over 2 minutes, repeated 
as necessary every 10 minutes to a total dose of 300 mg. Labetalol can 
also be given as a continuous infusion at an initial dose of 2 mg/min, 
adjusted according to the arterial pressure. 
The patient is kept NPO until gastrointestinal mobility resumes. 
A nasogastric tube, inserted during the operation, is kept to low 
continuous suction and irrigated hourly with saline. Antacid (Mylanta, 
30 ml or Riopan, 5 ml) is given via the nasogastric tube every 4 hours 
to keep the gastric pH >5. This dose of antacid is doubled when gastric 
pH is <5. Previous studies have demonstrated significantly less upper 
gastrointestinal hemorrhage in patients whose gastric pH is >5. 30 
Pulmonary complications are common and should be treated 
aggressively. The patient is turned every 2 hours. Pulmonary toilet is 
achieved by endotracheal suctioning, manual hyperinflations using a 
self-inflating ventilation bag and instillation of 3 ml saline with 
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repeat suctioning as needed every 2 hours. Sustained (15 second) manual 
hyperinflations of the lungs to recruit are used if arterial hypoxemia 
develops. The patient is weaned from mechanical ventilation using 
standard criteria for extubation (table 5). If there are no special 
problems, the patient can be extubated within 12-24 hours of surgery. 
Fluid management is very important. Most patients arrive in the 
lCU in a nonsteady state characterized by a much expanded extracellular 
fluid volume, increasing vasomotor tone, and hypothermia. We start 
basal fluid resuscitation with 5% dextrose in half-normal saline, 
infused at 125 mljhr. Since excessive administration of crystalloids 
may precipitate pulmonary edema, we use either plasma protein fraction 
or fresh frozen plasma to provide oncotic pressure and maintain 
intravascular volume. The goal of this initial therapy is to keep CVP 
at about 10 cm H20 and urine output at 0.5 ml/kgfh. Hypovolemia must be 
avoided since the combination of hypovolemia and cyclosporine increases 
the risk of postoperative renal failure. 
Immunosuppression is begun preoperatively. Cyclosporine and 
prednisone are the mainstays of immunosuppression in the liver 
transplant patient. The first dose of cyclosporine, 17.5 mg/kg, is 
given orally just before surgery, and the first bolus of steroids, 1 g 
methylprednisolone, is given intravenously at the time that the donor 
liver is revascularized. Postoperatively, 2 mg/kg cyclosporine is given 
intravenously every 12 hours until the patient resumes oral intake. 
Once the patient is able to take medications orally. 17.5 mg/kg 
cyclosporine is given in divided doses twice a day, as well as 2 mg/kg 
intravenously every l~ hours. Methylprednisolone, 200 mg, is given 
intravenously on the first day in 4 divided doses and tapered by 40 mg 
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per day until a maintenance dose of 20 mg/day is reached. Once the 
patient resumes oral intake, we switch to prednisone, 20 mg/day, orally. 
Cyc1osporine dosage is monitored by daily cyc1osporine trough levels in 
blood samples drawn one-half hour before the evening dose. Generally, 
whole-blood trough levels (by radioimmunoassay) of 800-1000 ng/ml are 
considered optimal. 
Since all patients are immunosuppressed and the procedure requires 
anastomosis of donor and recipient bile ducts, antibiotics with a 
spectrum appropriate for biliary tract pathogens such as Klebsiella, E. 
coli, and enterococcus are started preoperatively. Our practice is to 
give all patients ampicillin and cefotaxime, 1 g each intravenously 
every 6 hours. Other antibiotics are given as guided by culture 
results. Oral and vaginal candidiasis occur frequently in the liver 
transplant patient. To suppress these infections, we give mycostatin 
oral suspension four times a day and, for female patients, mycostatin 
vaginal suppositories three times a day. 
If hypokalemia occurs during the initial postoperative period, it 
is best treated with infusion of 20 mEq KGI rather than by adding KC1 to 
the maintenance intravenous fluids. Caution must be exercised to avoid 
hyperkalemia. The patient may be unable to excrete excess potassium 
since some degree of oliguria is common postoperatively. Further, graft 
necrosis may occur, with either primary nonfunction or hepatic artery 
thrombosis, and result in rapid increases in serum potassium. 
Although other centers treat postoperative liver transplant 
patients with narcotics, we generally avoid narcotics and sedatives, as 
these medications depend on hepatic metabolism. In addition, these 
drugs cause hypoventilation and secretion retention, increasing the risk 
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of postoperative pulmonary infection. Narcotics and sedatives also may 
alter mental status. Since improvement in mental status is an important 
sign of a functioning donor liver, we tend to avoid giving any drugs 
which may alter m.ental status. Instead of narcotics, we use mild 
sedatives such as antihistamines to blunt postoperative pain. If 
necessary, small doses of morphine sulfate or fentanyl are given, but 
only to patients who are awake and alert. To pediatric patients, 
however, we routinely give morphine sulfate for postoperative pain. 
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If there are no special problems or complications, the patient can 
usually be transferred to a surgical ward by the second or third 
postoperative day. 
2. Complications following liver transplantation 
a. Pulmonary complications 
The most common complications in the early postoperative period 
are pulmonary atelectases and pleural effusion. Atelectasis may lead to 
lobar collapse, which compromises oxygenation and, in these 
immunocompromised patients, rapidly leads to pneumonia. For these 
reasons, we aggressively treat atelectases with chest physical therapy, 
positioning, and nasotracheal suctioning. Since frequent nasotracheal 
suctioning can cause significant bleeding in these patients, we 
reintubate the trachea early if routine recruitment and pulmonary toilet 
procedures are ineffective. In patients with retained secretions, 
flexible fiberoptic bronchoscopy is performed repeatedly to help remove 
secretions. This aggressive treatment of segmental or lobar atelectasis 
has frequently improved oxygenation and reduces the risk of infection. 
Pleural effusions, primarily right-sided, are commonly seen 
postoperatively. During surgery when the suprahepatic inferior vena 
cava is clamped, a small portion of the right hemidiaphragm is usually 
included in the clamp. This trauma promotes right-sided pleural 
effusions. If the pleural effusion is small, it often resolves after 
several days of diuretic therapy. If the effusion is large, it may 
compress the underlying lung and cause atelectasis and pneumonia. In 
such cases, tube thoracostomy is indicated. Since liver transplant 
patients often have both abnormal coagulation an~ engorged intercostal 
collateral vessels, extreme care is exercised in placing the drainage 
catheter. We have seen massive bleeding in cases where these 
collaterals were injured. Accordingly, we often use a small, pigtail 
catheter inserted using the guidewire technique. 
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In many patients a significant postoperative metabolic alkalosis 
develops with partially compensatory respiratory acidosis. The degree 
of metabolic alkalosis is not related to the amount of bicarbonate given 
to the patient intraoperatively.31 This condition is usually seen in 
situations where there is primary graft failure. 
b. Hepatic complications 
Function of the transplanted liver may be altered by primary 
nonfunction, technical complications, or rejection. Primary nonfunction 
implies no evidence of initial function of the hepatic allograft after 
transplantation. It occurs infrequently, but is a very serious 
complication. Evidence of total hepatic failure includes profound 
hypoglycemia, uncorrectable coagulopathy, stage IV coma, new onset of 
renal failure, profound metabolic acidosis, cardiogenic shock, and 
markedly abnormal liver function tests. Prolonged ischemia of the liver 
before transplantation may lead to primary nonfunction. Donor hypoxemia 
before or during procurement and cold ischemia beyond 8-10 hours appear 
to be the most common reasons for primary nonfunction. However, some 
hepatic allografts, for unknown reasons, fail to function despite 
apparently uneventful procurement and transplantation. These allografts 
produce small amounts of thin watery bile, and the patient exhibits 
hypoglycemia, uncorrectable coagulopathy, depressed mental status, and 
abnormal liver function values. Infrequently, these allografts begin to 
function if the patient is carefully supported, but improvement rarely 
occurs after 48 hours of nonfunction. Patients with primary nonfunction 
should be considered for immediate retransplantation. Such patients are 
supported with infusions of fresh frozen plasma every 4 to 6 hours. 
Technical complications during surgery can affect hepatic 
function. These include surgical bleeding and graft failure from 
vascular occlusion at any of the four anastomoses as well as from 
problems with biliary tract reconstruction. The most common and 
devastating vascular complication of transplantation is hepatic artery 
thrombosis. Hepatic artery thrombosis presents with fever, malaise, and 
a positive blood culture for Klebsiella, E. coli, Pseudomonas, or 
enterococci. Signs of hepatic artery thrombosis us~ally occur in one of 
three general patterns (table 6).32 The first presentation, acute 
hepatic gangrene with sepsis and fulminant liver failure, necessitates 
urgent retransplantation. The second, delayed bile leak resulting from 
ischemic necrosis of the common bile duct, also requires 
retransplantation. The third, relapsing bacteremia, has been managed 
successfully with antibiotic therapy in some pediatric patients. A full 
course of intravenous antibiotics is given followed by a course of oral 
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suppressive antibiotic therapy. If the patient remains afebrile, with 
good liver function, retransplantation is not necessary. Most patients, 
however, will have persistent bacteremia and liver abscesses, 
eventually requiring retransplantation. Hepatic artery thrombosis 
should be suspected in all patients after liver transplantation who have 
unexplained fever, a bile leak, or a positive blood culture for gram 
negative organisms. Doppler ultrasonography of the liver has proven to 
be a useful screening device if a pulsatile artery is seen. If the 
vessel is not well seen, arteriography is required to make the 
definitive diagnosis. 
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Because of the threat of hepatic artery thrombosis, we do not 
vigorously treat elevated prothrombin time or low platelet count with 
fresh frozen plasma and platelet transfusions. Platelet count as low as 
30,000 and prothrombin time less than 30 seconds are not treated except 
in patients with active bleeding. 
Recurrent hepatic vein thrombosis in patients with the Budd-Chiari 
syndrome also has been seen. Because of the tendency to rethrombosis as 
well as primary hepatic artery thrombosis, anticoagulation therapy is 
given postoperatively. Adult patients are started on 10 ml per hour of 
Dextran 40 for 5 days. As soon as the prothrombin time is less than 18 
seconds, 50 units/kg of heparin is given intravenously every 12 hours. 
Aspirin, 40 mg, is given daily once the patient is on oral intake. 
Rapid development of ascites and abdominal pain has been reported by 
CaIne in association with acute portal vein thrombosis. 33 Severe 
variceal bleeding has been seen in the Pittsburgh series in acute portal 
vein thrombosis and associated rapidly deteriorating liver function. 
Retransplantation is indicated in these conditions. 
The incidence of bile duct complications has decreased with 
standardization of the technique of biliary duct reconstruction. Most 
bile leaks are delayed and, if suspected, must be promptly investigated 
and treated surgically to avoid sepsis. Suspected leakage can be 
confirmed through direct cholangiography, if a T-tube is present, or 
through endoscopic retrograde cholangiopancreatography in cases of 
choledocho-choledochostomy. None of these techniques can be used in 
patients who have a choledocho-jejunostomy. In these patients, a 
percutaneous transhepatic cholangiogram is necessary to define the 
biliary tract anatomy. 
Rejection is the most common cause for hepatic allograft 
dysfunction. It is often difficult to determine, however, whether poor 
hepatic function is due to rejection, infection, ischemia, a technical 
problem, or a combination of these. Often, fever in the early 
postoperative period may be the first indication of rejection. Other 
symptoms include loss of appetite, depression, vague upper abdominal 
pain, arthralgias, and myalgias. Examination of the allograft may 
disclose a swollen and hard liver and a tender abdomen with ascites. 
Deterioration in liver function tests and decreased quantity and quality 
of bile suggest rejection. Prolonged prothrombin time is rarely seen in 
rejection and occurs only in severe cases. The differentiation of 
infection from rejection is very important, since infection requires a 
decrease in immunosuppression, while rejection often requires an 
increase in immunosuppressive therapy. Acute rejection occurs most 
commonly in the second week after transplantation. 
We find liver biopsy to be invaluable in differentiating rejection 
from both ischemic injury and various forms of viral hepatitis, 
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especially that caused by cytomegalovirus. Hepatic rejection is 
characterized histologically by the triad of portal inflammation with 
/ 34 
mononuclear cells, bile duct damage, and venous endothelialitis. 
Other findings suggestive of rejection include intralobular 
hepatocellular regeneration, centrilobular bland hepatocellular 
necrosis, and few bile ducts. 35 Liver biopsy in late rejection reveals 
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less inflammatory infiltrate than in acute rejection, sparing 
centrilobular areas and demonstrating extensive periportal fibrosis 34 
with disappearance of bile ductules. 
If a T-tube is present, liver rejection is initially assessed with 
a T-tube cholangiogram. Comparison with the intraoperative 
cholangiogram is important. Pruning of the bile ducts within the liver 
suggests rejection. If a T-tube is not present, an ultrasound 
examination of the liver can be obtained to rule out bile duct 
obstruction. Finally, a computed tomogram of the liver may reveal areas 
of decreased attenuation, which are consistent with rejection. 
Initially, acute rejection is treated with steroid pulse therapy 
similar to the tapered steroid therapy given in the initial 
postoperative period. The 6-day steroid pulse is outlined in table 6. 
The cyclosporine trough level (whole blood RIA) is maintained at 800-
1000 ng/ml. Patients whose liver function appears to be getting worse 
despite steroid pulse therapy should be considered candidates for 
antilymphoscyte globulin (OKT-3). 
The monoclonal antibody OKT-3 (OrthocloneR, Ortho Pharmaceuticals, 
Ravitan, NJ), a T-cell-specific antilymphocyte globulin produced with 
the mouse hybridoma technique has been used in Pittsburgh for the 
treatment of acute rejection since 1984. It is given as a single daily 
dose of 5 mg intravenously over 15 minutes. The duration of therapy 
depends on graft response, but averages from 5 to 7 days. The most 
remarkable side effect of OKT-3 is bronchospasm, which is readily 
reversed with systemic epinephrine. Other side effects include fever, 
rigors, diarrhea, nausea, vomiting, chest tightness, and exacerbation of 
pulmonary edema in hypervolemic patients. 36 The protocol for 
administration of OKT-3 is given in table 7. Pulse steroid therapy and 
OKT-3 therapy now comprise a single course of antirejection therapy. 
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In the first 11 months of 1984, 20% of all liver transplant 
patients in Pittsburgh underwent retransplantation. 37 There were two 
clusters of retransplantation times, early (mostly for technical 
failures or primary non-function) corresponding to rejection at 1 and 2 
months postoperatively usually for acute rejection. Retransplantation 
within the first postoperative month is considered in patients with 
persistent hyperbilirubinemia of >10 mg/dl, rejection unresponsive to 
two full courses of antirejection therapy, or no evidence of correctable 
lesions. Patients with late rejection seldom respond to manipulation of 
immunosuppression and if they have marked elevation of hepatic enzymes 
should be considered early for retransplantation. 
Cyclosporine and prednisone are the mainstays of 
immunosuppression. Cyclosporine toxicity is a constant fear. As 
mentioned earlier, cyclosporine trough blood levels should be kept at 
between 800 and 1000 mg/ml. Since cyclosporine is lipid soluble and 
dependent on the enterohepatic circulation, its blood level may increase 
after T-tube clamping. Cyclosporine toxicity is manifest as 
hypertension, tremulousness, hypertrichosis, gingival hyperplasia, and 
nephrotoxicity (table 8). Cyclosporine may also impair liver function, 
but this is less common than acute or chronic nephrotoxicity. The most 
common cause of an increase in blood unea nitrogen and creatinine after 
transplantation is cyclosporine toxicity, which will respond promptly to 
reduction in the dosage given. Cyclosporine can produce a chronic 
interstitial fibrosis of the kidney, which may not be clinically 
apparent for many months 38 (Meyers NEJM). This lesion will 
significantly impair glomerular filtration rate and alter filtration 
fraction long before changes in serum creatinine or even creatinine 
clearance are detected. For these reasons, every effort is made to 
reduce cyclosporine doses to the lowest levels possible without 
compromising the immunosuppression of the patient. 
c. Renal complications 
Some degree of renal impairment develops in many patients after 
liver transplantation, even though most have normal renal function 
preoperatively. Most patients arrive in the lCU with an expanded 
extracellular fluid volume. ~espite this, they frequently have 
relatively low filling pressures (CVP less than 10 torr and pulmonary 
artery diastolic pressure less than 15 torr). If the urine output is 
greater than 20 mlfh, these patients require no diuretics, and usually 
the only fluid given is fresh frozen plasma or red blood cells to 
reverse coagulopathy or raise the hematocrit, respectively. Patients 
whose urine output falls below 20 mlfh and whose ventricular filling 
pressures are low are given boluses of crystalloids (PlasmalyteR or 
normal saline) or colloids (purified protein derivative) as necessary 
until urine output increases. Significant loss of third-space volume 
may necessitate massive, continuous fluid replacement, similar to the 
fluid requirements of septic patients. 
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In patients with reduced renal function preoperatively, renal 
failure often occurs postoperatively, occasionally severe enough to 
require hemodialysis. If the new liver functions promptly, however, 
renal function usually improves rapidly. Persistent postoperative renal 
failure, even in patients with the bepatorenal syndrome, is uncommon 
except when associated with systemic infection, poor allograft function, 
or other complications. 
The administration of such nephrotoxic drugs as antibiotics and 
cyclosporine must be carefully monitored and dosages manipulated 
according to renal function and serum levels. Cyclosporine 
nephrotoxicity usually complicates renal insufficiency rather than 
induces it, provided trough levels are kept in the recommended range 
(800-1000 ng/ml). 
d. Bleeding and coagulation problems 
Substantial improvement in the technical aspects of both 
anesthetic and surgical management of liver transplantation has 
significantly reduced the perioperative coagulopathy uniformly seen in 
the past. The coagulation defects seen most commonly on arrival in the 
SICU are prolonged prothrombin time, partial thromboplastin time, and 
thrombocytopenia. However, with appropriate blood component therapy 
(such as packed red blood cells, fresh frozen plasma, platelets, 
cryoprecipitate, and epsilon aminocaproic acid), bleeding due to 
coagulopathy is rarely a problem in the SICU. Inability to correct 
coagulopathy by routine replacement of blood components suggests poor 
graft function. A continued need for red blood cell transfusions 
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postoperatively generally indicates the need for early reexploration for 
hemostasis, not the presence of coagulopathy. 
e. Infection 
We do not place the liver transplantation patient in a protective 
isolation environment in the lCU. This is in contrast with the 7-day 
obligatory protective isolation in the lCU used by the Cambridge group. 
Rigid application of standard hygienic principles limits the spread of 
infection by personnel. Indeed, the overwhelming threat to these 
immunocompromised individuals is their own gastrointestinal flora. 
During the initial postoperative period, fever is uncommon. If 
fever is present, it must be thoroughly evaluated. Our protocol for 
postoperative fever evaluation is shown in table 9. In addition, other 
tests are used as indicated. For example, acute serum titers for CMV, 
tuberculosis skin test, legionella titers, and hepatitis screening may 
be obtained. If indicated by clinical examination, a lumbar puncture is 
performed to rule out central nervous system infection. Ultrasonography 
and computed tomography of the abdomen are very useful in evaluating 
hepatobiliary duct size and to look for intraabdominal fluid 
collections. Fiberoptic bronchoscopy with bronchoalveolar lavage (BAL) 
and open lung biopsy are also useful techniques to identify the 
causative agent in the presence of pneumonia, especially if pneumocystis 
carinii infection is suspected. We treat new pulmonary infiltrates of 
unknown etiology empirically with erythromycin and sulfamethoxazole-
trimethoprim to cover both legionella and pneumocystis carinii 
infections until final culture results are known. 
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From 1981 to 1983, 81% of all liver transplant patients in 
Pittsburgh had at least one infection. 39 This high infection rate is 
most likely related to immunosuppression, use of antibiotics, and 
preoperative malnutrition. Further, use of antacids permits bacterial 
overgrowth in the stomach. Gastrointestinal surgery for biliary 
reconstruction also may contribute to the high frequency of 
postoperative infection, as does a defective reticuloendothelial system. 
Sepsis remains a major cause of morbidity and mortality in patients 
after retransp1antion. 37 
Fungal infection occurs in 42% of our liver transplant patients, 
usually within 1 month of transplantation. Fungal infections are more 
common when steroids and antibiotics are used preoperatively and if the 
duration and number of operative procedures increase. Fungal infections 
are also associated with increasing duration of perioperative antibiotic 
administration, bacterial infections, and rejection treated with steroid 
boluses. For unknown reasons, patients with primary biliary cirrhosis 
have a low incidence of fungal infections. Candida is the most common 
fungal organism isolated from these patients, while aspergillus is the 
next most frequent. Invasive aspergillosis has been uniformly fata1. 40 
Significant monilia in the sputum, blood, urine, bile, or drains is 
treated with intravenous amphotericin B. 
Both herpesvirus and CMV have caused significant infections in 
liver transplantation recipients. Overwhelming infections with these 
viruses have been fatal. Documented herpesvirus infections are treated 
with daily acyclovir,S mg/kg, in 3 divided doses for 10-14 days. At 
present, there is no treatment for CMV infections. As is the case for 
all significant infections in these immunocompromised hosts, one of the 
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first steps of therapy is a significant reduction in immunosuppression. 
Use of bolus injections of steroids for "stress" in the presence of 
major infection is unwarranted and dangerous. However, maintenance 
doses of steroids in steroid-dependent patients should be continued. 
f. Nutri don 
Postoperative ileus usually resolves by the third or fourth 
postoperative day. Assuming that liver function is acceptable and there 
are no other contraindications, progressive oral intake is initiated 
with liquids and advanced to an unrestricted diet. For patients who 
have a functional gastrointestinal tract, but are either unable to eat 
or at high risk for aspiration, a thin silastic feeding tube is passed 
beyond the pylorus, and enteral feeding is begun. Intravenous 
hyper alimentation is reserved for patients whose gastrointestinal tract 
cannot be used for nutrition. In contrast, CaIne begins total 
parenteral nutrition on postoperative day 2 via an intraoperatively 
placed central venous catheter. 33 
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Table 1. Metabolic Diseases of the Liver 
Associated with liver injury 
Wilson's disease 
Hemochromatosis 
Alpha-l antitrypsin deficiency 
Tyrosinemia 
Glycogen storage disease types I and IV 
Protoporphyria 
Not associated with liver injury 
Hemophilia 
Urea cycle enzyme deficiencies 
Phenylketonuria 
Hyperlipoproteinemia type 2 
Crigler-Najjar syndrome 
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Table 2. Effect of Azathioprine Versus Cyclosporine on Survival After 
Primary Liver Transplantations* 
Number of 
Patients (%) 
Survived 
Died 
Azathioprine 
and 
Prednisone 
170 (19.1) 
28 (16.5) 
142 (83.5) 
Cyclosporine 
and 
Prednisone 
720 (80.9) 
494 (68.6) 
226 (31.6) 
Total 
890 (100) 
522 (58.6) 
368 (41.4) 
*890 primary liver transplantations with observations through 
November 1, 1986. 
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Table 3. Graft Status at the Beginning of March 1987 and One-year 
Survival in Liver Transplant Recipients Treated with OKT3 
Group 
Number of 
Grafts 
1 119 
2 110 
3 21 
1-3 250 
No OKT3* 362 
Graft Status 
Functioning 
57 (47.9%) 38 (31.9%) 
79 (71.8%) 17 (15.5%) 
10 (47.6%) 8 (38.1%) 
146 (58.4%) 63 (25.2%) 
181 (50.0%) 90 (24.9%) 
24 (20.2%) 
14 (12.7%) 
3 (14.3%) 
41 (16.4%) 
91 (25.1%) 
I-Year Survival 
Graft Patient 
49.4% 
74.3% 
71.4% 
62.0% 
53.3% 
62.4% 
82.2% 
87.5% 
73.4% 
71.8% 
*For comparative purposes data for all liver transplant recipients not 
receiving OKT3 from August 1983 to June 1986 are added. l 
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Table 4. Orders for Postoperative Care of Adult Liver Transplant 
Patients 
-Diagnosis: SIP orthotopic liver transplant 
-Condition: Critical 
-Vital Signs: Q15 min until stable, then hourly 
Hourly CVP, I & 0 
-NPO 
-Bedrest until tracheal extubation, then up as tolerated 
-Respiratory care per lCU 
-Foley catheter to closed gravity drainage 
-Jackson-Pratt drains to closed bulb suction 
-T-tube to closed drainage 
38 
-NG tube to low continuous suction-irrigate with 30 m1 normal saline QIH 
-Riopan 5 ml Q2H per NG tube clamp for 15 min 
Double dose if gastric pH < 5 
-Turn Q2H, endotracheal suctioning Q4H, postural drainage and clapping 
Q4H 
-D5 1/2 NS at 125 m1/hr 
-Cyc1osporine 2 mg/kg iv Q12H at 10 a.m. and 10 p.m. daily 
-Methylprednisolone: 50 mg iv Q6H X 4, then 
40 mg iv Q6H X 4, then 
30 mg iv Q6H X 4, then 
20 mg iv Q6H X 4, then 
20 mg iv Q12H X 2, then 
20 mg iv QD 
-Cyclosporine trough level from 9:30 p.m. blood 
Table 4. (cont.) 
-Ampicillin 1.0 gm iv Q6H X Sd 
-Cefotaxime 1.0 gm iv Q6H X 5d 
-Mycostatin 5 m1 swish and swallow QID once NG tube is out (and 
myostatin vaginal suppository TID to female patients) 
-CRX now and daily 
-STAT, then Q6H X 4: CBC, PT, PTT, platelets 
-Q6H X 4 electrolytes, BUN, creatinine, glucose, amylose 
-Daily labs: CBC, diff, PT, PTT, platelets, electrolytes, Ca, P, Mg, 
BUN, creatinine, bilirubin (TID), SGOT, SGPT, a1k phos, GTP, total 
protein, albumin, and amylase 
-Keep 4 units packed red cells on hold 
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Table S. Criteria for Weaning from Mechanical Ventilation and Tracheal 
Extubation 
-Hemodynamically stable patient 
-Alert patient able to defend airway 
-Pa02 > 60 torr on an F102 S 0.4 and S 5 cm H20 PEEP 
-Maximum inspiratory force > 20 cm H20 
-Vital capacity ~ 10 ml(kg 
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Table 6. Clinical Presentations of Hepatic Artery Thrombosis 
1. Fulminant hepatic necrosis 
Frank hepatic gangrene 
Rapid rise in serum transaminasis 
Rapid clinical deterioration 
2. Delayed biliary leak 
Ischemic necrosis of the bile ducts with subhepatic fluid 
collection 
Drainage of bile through abdominal tubes 
Frank bile peritonitis 
Bacteremia 
Changes in the liver chemistry profile similar to those 
seen with rejection. 
3. Relapsing bacteremia 
Indolent clinical course 
Usually only minor abnormalities in 
liver chemistry profile 
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Table 7. Protocol for Administration of OKT-3 
I. Evaluation before administration 
A. Determined within 24 hours of first dose: 
l. Physical examination recorded in chart 
2. Chest X-ray reviewed by house officer 
3. Hct, WBC, diff, platelets PT, PTT, lytes, BUN, creat, 
P04 , glucose, SGOT, SGPT, alk phos, GGTP, bili T/D, 
total protein, albumin. 
4. Weight recorded on chart. 
B. Patient should receive special consideration if: 
1. Obviously in respiratory distress 
2. Obviously fluid overloaded 
3. Neutropenia (WBC < 3000) 
II. During administration 
A. High risk patients and all pediatric patients should be 
transferred to an lCU to receive the first two doses 
Ca++ 
B. All patients must have a functioning IV line in place and an 
infusion pump should be available 
C. All patients will have O2 available 
D. A crash cart with intubation equipment will be available 
E. All patients will have a cardiac monitor 
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, 
F. Epinephrine should be available at bedside in doses appropriate 
for the patient 
G. One gram of solu-cortef should be available 
Table 7. (cont.) 
III. Medications 
A . All patients receive one hour before OKT-3: 
• 
1. Solucortef 1 gm IV if > 30 kg 1st day 
500 mg to 19m IV if < 30 kg 1st day 
250 mg IV if > 30 kg 2nd day 
125 mg IV if < 30 kg 2nd day 
2. Benadry1 15-25 mg IV/25-50 mg po 
3. Tylenol 325-650 mg po or 650 mg pr 
B. Administration of OKT-3 
1. Must be given by physician 
2. > 30 kg 5 ml over 5 min by IV push 
< 30 kg 2.5 to 5 ml over 5 min by IV push 
IV. Nursing - write "VS per OKT-3 protocol", which equals: 
A. Days 1 and 2 
B. 
VS baseline preadministration temp, pulse, respiratory rate, 
and blood pressure, then 
q 15 min X 2 hours 
q 30 min X 2 hours 
q 1 hour X 2 hours 
then q 2 h 
Days 3 through 14 
l. VS baseline as day 1 and 2 
q 30 min X 1 hour 
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Table 7. (cont) 
q 2 hours until stable 
then q 4 hours 
2. Observe for: 
a. fever (most patients will have some) 
b. chills (most patients will have some) 
c. diarrhea 
d. nausea and vomiting 
e. chest pain or respiratory distress 
3. Call house office for: 
a. temp > 39 
b. fall in systolic BP > 20 mmHg 
c. respiratory rate > 35 
d. any chest pain 
e. any respiratory distress 
V. Treatment of anaphylactic reactions 
1. STAT arterial blood gases 
2. Start 02 by nasal cannula 2-4 liters/min 
3. Solucortef 200-400 mg IV push if no relief or respiratory 
distress, then 
4. Epinephrine 1:1000 solution, give 0.01 mg/kg (maximum dose: 
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0.3 ml) SC. Repeat q 5-15 min to a maximum of 3 doses depending 
upon response. 
5. Start epinephrine infusion at 0.1 ug/kg/m1 up to a maximum of 
1 mg/kg/min (1:100 vial 15 mg/250 cc D5Y). 
Table 7. (cont.) 
6. Failure to respond at any point is indication for prompt 
intubation and transfer to the lCU. 
7. Serial ABGs should be obtained by house officer until symptoms 
resolve. 
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Table 8. Side Effects of Cyclosporine 
Nephrotoxicity (reversible) 
Hypertension 
Hyperkalemia 
Hepatotoxicity 
Hirsutism 
Gingival hyperplasia 
Tremor/Seizures 
Regional flushing 
Vague abdominal discomfort 
Breast fibroadenoma in women 
Lymphoproliferative disease 
--------------- ... -.- .... ~ .... 
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Table 9. Initial Evaluation for Postoperative Fever 
Physical examination 
Chest and abdominal radiographs 
Sputum gram stain, culture, and sensitivity 
Culture/sensitivity - drains, tubes, open wounds 
Culture/sensitivity - long term indwelling lines 
Arterial and venous blood cultures 
Urine for cytomegalovirus 
Throat swabs for cytomegalovirus 
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LEGENDS 
Figure 1 Total United States experience with extra-renal transplants 
through 1985. 
Figure 2 
1980. 
Number of liver transplants performed in Pittsburgh since 
Figure 3 Indications for 720 liver transplants performed in 
Pittsburgh. 
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Figure 4 Acturial data describing the relation between number of HLA-A 
loci mismatches and graft survival following liver transplantation. 
Although not significant (p - 0.054), survival tends to be better as the 
number of HLA-A loci mismatches increases. 
Figure 5 Acturial data describing the relation between number of HLA-
DL loci mismatches and graft survival following liver transplantation. 
HLA-DR mismatches do not significantly affect graft survival. 
Figure 6 Relation between patient age and survival following liver 
transplantation. 
Figure 7 Illustrations of the final biliary reconstruction following 
liver transplantation using either choledocho-choledochostomy with T-
tube start (left) or choledocho-jejunostomy to a Roux-en-Y limb of 
jejunum (right). 
Figure 8 Comparison of patient survival rates following liver 
transplantation with either cyclosporine (dashed line) or azathioprine 
(solid line) are used for immunosuppression. 
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